Johnson & Johnson/Janssen COVID-19 vaccine
CDC recommends restarting Johnson & Johnson's COVID-19 vaccine
Contributed By:The 411 News
Use of vaccine comes with warnings about possible side effects
After the temporary pause, CDC and FDA have recommended that use of the J&J/Janssen COVID-19 Vaccine resume in the United States, effective April 23, 2021.
Reports of serious blood cloths or thrombosis in six women, with 1 death, led to the pause of the vaccine on April 12. Nearly all reports of blood clots with low platelets have been in adult women younger than 50 years old.
After a review of all available data at this time, the CDC and FDA reported that the J&J COVID-19 Vaccine’s known and potential benefits outweigh its known and potential risks.
The pause allowed CDC to communicate with healthcare providers and re-emphasize the importance of reporting severe events in people who have received this vaccine, as well as how to report such events. The pause also gave experts time to carefully review all available data and conduct a risk-benefit analysis around the use of this vaccine.
Clotting occurred at a rate of about 7 per 1 million vaccinated women between 18 and 49 years old. For women 50 years and older and men of all ages, clotting was even more rare.
The recommendation to restart administering the J&J vaccine comes with a warning.
For three weeks after receiving the vaccine, be on the lookout for possible symptoms of a blood clot with low platelets. Signs include:
• Severe or persistent headaches or blurred vision
• Shortness of breath
• Chest pain
• Leg swelling
• Persistent abdominal pain
• Easy bruising or tiny blood spots under the skin beyond the injection site
Seek medical care right away if you develop one or more of these symptoms. If you have any questions or concerns, call your doctor, nurse, or clinic.
Story Posted:04/25/2021
|
